IL255898A - Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases - Google Patents
Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseasesInfo
- Publication number
- IL255898A IL255898A IL255898A IL25589817A IL255898A IL 255898 A IL255898 A IL 255898A IL 255898 A IL255898 A IL 255898A IL 25589817 A IL25589817 A IL 25589817A IL 255898 A IL255898 A IL 255898A
- Authority
- IL
- Israel
- Prior art keywords
- initiation
- inhibition
- translation
- diseases
- treatment
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000000977 initiatory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000003233 pyrroles Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169376P | 2015-06-01 | 2015-06-01 | |
| PCT/US2016/035288 WO2016196644A1 (en) | 2015-06-01 | 2016-06-01 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL255898A true IL255898A (en) | 2018-01-31 |
Family
ID=56118071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255898A IL255898A (en) | 2015-06-01 | 2017-11-26 | Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10537558B2 (enExample) |
| EP (1) | EP3303332A1 (enExample) |
| JP (1) | JP6707630B2 (enExample) |
| CN (1) | CN108349962A (enExample) |
| BR (1) | BR112017025851A2 (enExample) |
| CA (1) | CA3025492A1 (enExample) |
| IL (1) | IL255898A (enExample) |
| MX (1) | MX2017015456A (enExample) |
| WO (1) | WO2016196644A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017015456A (es) | 2015-06-01 | 2018-11-29 | Bantam Pharmaceutical Llc | Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. |
| MX2019006296A (es) | 2016-11-30 | 2019-11-12 | Bantam Pharmaceutical Llc | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. |
| WO2018102453A1 (en) * | 2016-11-30 | 2018-06-07 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| CN111918865B (zh) | 2018-03-30 | 2023-10-27 | 住友化学株式会社 | 杂环化合物和含有该杂环化合物的有害节肢动物防除组合物 |
| JP2021527059A (ja) * | 2018-06-07 | 2021-10-11 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ | 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断 |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
| US12358905B2 (en) * | 2019-05-31 | 2025-07-15 | Bantam Pharamceutical, LLC | Methods for making thiazolypyrazole carboxylic acids and intermediates therefor |
| US12435076B2 (en) | 2019-11-01 | 2025-10-07 | Unimatec Co., Ltd. | Fluorine-containing pyrimidine compound and method for producing same |
| MX2022010944A (es) | 2020-03-03 | 2022-11-09 | Pic Therapeutics Inc | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. |
| TW202315621A (zh) | 2021-08-25 | 2023-04-16 | 美商皮克醫療公司 | Ｅｉｆ４ｅ抑制劑及其用途 |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342851A (en) * | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
| IT1301968B1 (it) | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| ATE252576T1 (de) * | 1999-12-03 | 2003-11-15 | Pfizer Prod Inc | Heteroarylphenylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel |
| US6900219B2 (en) | 2002-04-04 | 2005-05-31 | Cv Therapeutics, Inc. | ABCA-1 elevating compounds |
| CA2520870A1 (en) | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| US20070060584A1 (en) * | 2003-04-18 | 2007-03-15 | Chakravarty Prasun K | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| WO2007138110A2 (en) | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| AR068063A1 (es) * | 2007-08-27 | 2009-11-04 | Basf Plant Science Gmbh | Co mpuestos de pirazol para controlar plagas de invertebrados |
| WO2009123316A1 (ja) * | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
| HRP20150842T1 (hr) | 2008-04-28 | 2015-09-11 | Kyorin Pharmaceutical Co., Ltd. | Derivati ciklopentilakrilamida |
| US20140031547A1 (en) * | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
| CA2888889A1 (en) | 2012-10-22 | 2014-05-01 | Egenix, Inc. | Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e |
| CN106458992B (zh) | 2014-03-27 | 2019-03-15 | 默克专利股份公司 | 吡啶基哌啶 |
| JP2018513870A (ja) | 2015-04-24 | 2018-05-31 | シンジェンタ パーティシペーションズ アーゲー | 硫黄置換５員環複素環を有する殺有害生物的に活性な多環式誘導体 |
| MX2017015456A (es) | 2015-06-01 | 2018-11-29 | Bantam Pharmaceutical Llc | Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. |
-
2016
- 2016-06-01 MX MX2017015456A patent/MX2017015456A/es unknown
- 2016-06-01 WO PCT/US2016/035288 patent/WO2016196644A1/en not_active Ceased
- 2016-06-01 US US15/578,585 patent/US10537558B2/en active Active
- 2016-06-01 JP JP2018515175A patent/JP6707630B2/ja not_active Expired - Fee Related
- 2016-06-01 BR BR112017025851-0A patent/BR112017025851A2/pt not_active Application Discontinuation
- 2016-06-01 CN CN201680045318.9A patent/CN108349962A/zh active Pending
- 2016-06-01 EP EP16728546.9A patent/EP3303332A1/en not_active Withdrawn
- 2016-06-01 CA CA3025492A patent/CA3025492A1/en not_active Abandoned
-
2017
- 2017-11-26 IL IL255898A patent/IL255898A/en unknown
-
2020
- 2020-01-21 US US16/748,429 patent/US11602526B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180311218A1 (en) | 2018-11-01 |
| WO2016196644A1 (en) | 2016-12-08 |
| CN108349962A (zh) | 2018-07-31 |
| US10537558B2 (en) | 2020-01-21 |
| JP2018521119A (ja) | 2018-08-02 |
| US11602526B2 (en) | 2023-03-14 |
| EP3303332A1 (en) | 2018-04-11 |
| JP6707630B2 (ja) | 2020-06-10 |
| US20200261424A1 (en) | 2020-08-20 |
| BR112017025851A2 (pt) | 2018-10-16 |
| MX2017015456A (es) | 2018-11-29 |
| CA3025492A1 (en) | 2016-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266930A (en) | Modified pyrazole compounds and methods of using them for the treatment of hyperproliferative diseases | |
| IL266931A (en) | Methods of using modified pyrazole and pyrazole compounds for the treatment of hyperproliferative diseases | |
| SI4122464T1 (sl) | Terapevtske kombinacije za zdravljenje bolezni jeter | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| EP3668993A4 (en) | HEPATIC DISEASE TREATMENT METHODS | |
| IL275321A (en) | Treatment of diseases associated with the expression of DUX4 | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL254568A0 (en) | Compounds and forms for the treatment of female sexual disorders | |
| IL261277A (en) | Combination therapies for treatment of spinal muscular atrophy | |
| ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
| IL320533A (en) | Methods and compositions for treating disorders and diseases involving RDH12 | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| ZA201705877B (en) | Method of treating diseases | |
| IL253847A0 (en) | Methods of treating diseases | |
| HUE054420T2 (hu) | Folyamatos eljárás terápiás fehérje heterogenitásának csökkentésére | |
| IL279497A (en) | Treatment of protein in the urine | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| EP3251699A4 (en) | Composition and method for treatment of neuropsychiatric disorders | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| IL265596A (en) | Methods for treating ocular disease using inhibitors of csf-1r | |
| ZA202001927B (en) | Method for treating tnf alpha-related diseases | |
| IL252543A0 (en) | Compounds for the treatment of degenerative retinal tissues | |
| EP3402531A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |